We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Parathyroidectomy in Endstage Renal Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00745719
Recruitment Status : Completed
First Posted : September 3, 2008
Last Update Posted : January 18, 2017
Information provided by (Responsible Party):

September 1, 2008
September 3, 2008
January 18, 2017
March 2007
September 2011   (Final data collection date for primary outcome measure)
Change in vascular and valvular calcium scores [ Time Frame: 12 months ]
Same as current
Complete list of historical versions of study NCT00745719 on ClinicalTrials.gov Archive Site
  • Change in bone mineral density [ Time Frame: 12 months ]
  • change in aortic pulse wave velocity, [ Time Frame: 12 months ]
  • change in left ventricular mass, volume and function [ Time Frame: 12 months ]
  • changes in quality of life scores [ Time Frame: 12 months ]
  • changes in iPTH [ Time Frame: 6 and 12 months ]
  • changes in Serum calcium and phosphate [ Time Frame: 6 and 12 months ]
  • changes in alkaline phosphatase [ Time Frame: 6 and 12 months ]
  • changes in handgrip strength [ Time Frame: 12 months ]
  • changes in subjective global assessment [ Time Frame: 6 and 12 months ]
  • changes in serum albumin [ Time Frame: 6 and 12 months ]
  • changes in inflammatory marker [ Time Frame: 12 months ]
  • changes in HOMA index [ Time Frame: 6 and 12 months ]
Change in left ventricular mass and volume, left ventricular systolic and diastolic function, augmentation index and pulse wave velocity, inflammatory marker, HOMA, quality of life score, handgrip, bone biopsy [ Time Frame: 12 months ]
Not Provided
Not Provided
Parathyroidectomy in Endstage Renal Disease
A Pilot Study to Evaluate the Efficacy of Total Parathyroidectomy in Retarding Cardiovascular Calcification in End-stage Renal Disease Patients
To test the hypothesis that total parathyroidectomy retards cardiovascular calcification, improves bone mineral density, reduces cardiac hypertrophy and arterial stiffening in end-stage renal disease patients on maintenance dialysis.
Secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease contributes to increased cardiovascular morbidity and mortality via different mechanisms. Uncontrolled hyperparathyroidism is associated with left ventricular hypertrophy and has been implicated in the development of cardiac interstitial fibrosis and diastolic dysfunction.
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Endstage Renal Disease
Procedure: parathyroidectomy
total parathyroidectomy with forearm autografting
Other Name: total parathyroidectomy with forearm autografting
Experimental: 1
surgical total parathyroidectomy with forearm autografting
Intervention: Procedure: parathyroidectomy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
January 2012
September 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Endstage renal disease patients receiving either long-term hemodialysis or peritoneal dialysis treatment, with elevated intact parathyroid hormone (iPTH) levels > 500pg/ml on two or more occasions.
  • Patients with parathyroid nodular or diffuse hyperplasia identified by ultrasound imaging or radioisotope scan.
  • Patients who provide informed consent for the study.

Exclusion Criteria:

  • Patients with significant background valvular heart disease
  • Patients who are unfit for general anaesthesia
  • Patients with acute myocardial infarction within recent two months
  • Patients with poor general condition
  • Patients with plans for living related kidney transplant within 1 year
  • Patients with previous history of parathyroidectomy
  • Patients with calciphylaxis
  • Patients with underlying active malignancy
  • Patients with contraindication for MRI
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Hong Kong
Not Provided
Plan to Share IPD: No
Dr. Angela Yee-Moon Wang, The University of Hong Kong
The University of Hong Kong
Not Provided
Principal Investigator: Angela YM Wang, MD, PhD Queen Mary Hospital, University of Hong Kong
The University of Hong Kong
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP